SCHEMBL3207151

SCHEMBL3207151

O=C(O)c1cncc(N(Cc2cncs2)c2ccc(OC(F)F)c(OC(F)F)c2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 9/20 0.36
PDE4D Q08499 8/20 0.36
PDE4A P27815 5/20 0.36
PDE4C Q08493 4/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.33
RXRA P19793 3/20 0.32
F11 P03951 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
ABCB11 O95342 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
PARP15 Q460N3 1/20 0.31
PARP10 Q53GL7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206120 0.95 RXRA (0.39) PDE4BPDE4DPDE4APDE4CKMT2A
SCHEMBL3214864 0.91 PDE4D (0.33) PDE4BPDE4DPDE4APDE4CKMT2A
SCHEMBL3122844 0.91 PDE4A (0.40) PDE4BPDE4DPDE4APDE4CRXRA
SCHEMBL3123327 0.90 PDE4A (0.38) PDE4BPDE4DPDE4APDE4CKMT2A
SCHEMBL3206219 0.87 L3MBTL1 (0.34) PDE4BPDE4DPDE4APDE4CKMT2A
SCHEMBL3125745 0.87 RXRA (0.48) PDE4BPDE4DPDE4APDE4CRXRA
SCHEMBL3129911 0.86 RXRA (0.39) PDE4BPDE4DPDE4APDE4CRXRA
SCHEMBL3125356 0.85 RXRA (0.39) PDE4BPDE4DPDE4APDE4CKMT2A
SCHEMBL3131039 0.85 RXRA (0.39) PDE4BPDE4DPDE4APDE4CKMT2A
SCHEMBL3129478 0.85 CTSL (0.37) PDE4BPDE4DPDE4APDE4CKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.